1620 Investment Advisors, Inc. Intellia Therapeutics, Inc. Transaction History
1620 Investment Advisors, Inc.
- $142 Million
- Q3 2025
A detailed history of 1620 Investment Advisors, Inc. transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, 1620 Investment Advisors, Inc. holds 1,300 shares of NTLA stock, worth $11,271. This represents 0.02% of its overall portfolio holdings.
Number of Shares
1,300
Previous 1,300
-0.0%
Holding current value
$11,271
Previous $12,000
83.33%
% of portfolio
0.02%
Previous 0.01%
Shares
1 transactions
Others Institutions Holding NTLA
# of Institutions
339Shares Held
98.4MCall Options Held
3.26MPut Options Held
1.55M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl11.9MShares$103 Million1.45% of portfolio
-
Vanguard Group Inc Valley Forge, PA11MShares$95.8 Million0.0% of portfolio
-
Black Rock Inc. New York, NY9.6MShares$83.2 Million0.0% of portfolio
-
Morgan Stanley New York, NY6.02MShares$52.2 Million0.01% of portfolio
-
Contrarius Group Holdings LTD Hamilton, D05.89MShares$51.1 Million4.6% of portfolio
About Intellia Therapeutics, Inc.
- Ticker NTLA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,011,800
- Market Cap $659M
- Description
- Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...